Functional studies have conducted inhibitor assays in several malignant tumors, including MM [20, 40], pancreatic cancer [19], ovarian cancer [41], and prostate cancer [42] using IRE1α-XBP1 inhibitors both in vitro and in vivo. This evidence concerns the gene XBP1 and ovarian carcinoma.